<DOC>
	<DOCNO>NCT00511966</DOCNO>
	<brief_summary>The objective Observational study evaluate hygiene-dietetic habit co-adjuvant treatment pharmacologic therapy use treat Gastroesophageal Reflux .</brief_summary>
	<brief_title>Influence Hygiene-dietetic Habits Treatment Adherence Effectiveness Gastroesophageal Reflux Illness Treatment With Rabeprazol</brief_title>
	<detailed_description>Gastroesophageal Reflux illness multifactor pathology common mechanism : prolonged exposure esophageal mucosa gastric solution . Modification life style hygiene-dietetic habit frequently recommend initial therapeutic instrument Gastroesophageal Reflux pathology . But agreement effectiveness habit improvement illness . Different clinical practice guidance show contradiction effectiveness change hygiene-dietetics habits life style . The high effectiveness new pharmacologic treatment Gastroesophageal Reflux pathology make necessary review role hygiene-dietetic habit illness . Proton pump inhibitor ( PPI ) act final step gastric secretion . PPI 's block ATP-ase H+/K+ gastric parietals cell . This mechanism generate high acid inhibition , long inhibition produce H2-receptor antagonist . It describe inhibition acid secretion produce recovery gastroesophageal pathology high percentage patient resistant conventional drug . This observational , multicenter , open prospective study . The primary objective evaluate hygiene-dietetic habit co-adjuvant Rabeprazol treatment Gastroesophageal Reflux . It expect include 570 patient Gastroesophageal pathology erosive non-erosive acute chronic treat Rabeprazol per clinical practice , 20mg per day , orally , 8 week . All data collect prospective include follow : demographic data , progress pathology , change hygiene-dietetic habit , treatment adherence , concomitant treatment adverse event . Observational Study - No investigational drug administer</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Patients Gastroesophageal pathology erosive nonerosive acute chronic treat Rabeprazol per clinical practice Patients pregnant lactate Other gastrointestinal pathology Intestinal gastric survey Other severe concomitant pathology Drug abuse use NSAIs ( NonSteroidal AntiInflammatories ) 3 days/week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Gastroesophageal Reflux</keyword>
	<keyword>Rabeprazole</keyword>
</DOC>